Skip to content
value.today

Spine BioPharma, LLC

Total raised
$39 M
6 rounds on record
Latest round
$14 M
Sep 2024
First round on record
Mar 2021
Today
Private
No later event on record

Funding rounds

6 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Spine BioPharma, LLC
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2024$14 MNo. 6$10 to $50 million

Spine BioPharma, LLC: Raise no. 6, Sep 2024

Investors in this round

10 investors had bought by the notice of Dec 18, 2024: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$14 M of $24 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fran R. Magee · Executive Officer · Chief Technology Officer
  • Jason J. Gallagher · Executive Officer · Chief Commercial Officer/Chief Operations Officer
  • Marc R. Viscogliosi · Executive Officer, Director · Director and Chief Executive Officer of the Issuer
  • Frank R. Cammisa, MD · Director
  • John J. Viscogliosi · Director
  • Thomas R. Bumol, PhD · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Offering is Convertible Notes.”

Signed by Marc R. Viscogliosi, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 18, 2024. Read the notice at the SEC.

equity, debtSEC
Oct 2023$2 MNo. 5$2 to $10 million

Spine BioPharma, LLC: Raise no. 5, Oct 2023

Investors in this round

3 investors had bought by the notice of Oct 11, 2023: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $15 M offered; $13 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fran R. Magee · Executive Officer · Chief Technology Officer and Chief Operating Officer
  • Marc R. Viscogliosi · Executive Officer, Director · Director and Chief Executive Officer of the Issuer
  • Frank R. Cammisa, MD · Director
  • John J. Viscogliosi · Director
  • Thomas R. Bumol, PhD · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Offering is Convertible Notes.”

Signed by Marc R. Viscogliosi, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 11, 2023. Read the notice at the SEC.

equity, debtSEC
Aug 2023$2 MNo. 4Under $2 million

Spine BioPharma, LLC: Raise no. 4, Aug 2023

Investors in this round

1 investor had bought by the notice of Aug 31, 2023: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $13 M offered; $11 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fran R. Magee · Executive Officer · Chief Technology Officer and Chief Operating Officer
  • Marc R. Viscogliosi · Executive Officer, Director · Director and Chief Executive Officer of the Issuer
  • Frank R. Cammisa, MD · Director
  • John J. Viscogliosi · Director
  • Thomas R. Bumol, PhD · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Offering is Class B Preferred Stock.”

Signed by Marc R. Viscogliosi, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 31, 2023. Read the notice at the SEC.

equitySEC
Mar 2022$13 MNo. 3$10 to $50 million

Spine BioPharma, LLC: Raise no. 3, Mar 2022

Investors in this round

6 investors had bought by the notice of Mar 24, 2022: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$13 M of $30 M offered; $17 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Fran R. Magee · Executive Officer · Chief Technology Officer and Chief Operating Officer
  • Marc R. Viscogliosi · Executive Officer, Director · Director and Chief Executive Officer of the Issuer
  • Frank R. Cammisa, MD · Director
  • John J. Viscogliosi · Director
  • Thomas R. Bumol, PhD · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The Offering is Class B Preferred Stock.”

Signed by Marc R. Viscogliosi, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 24, 2022. Read the notice at the SEC.

equitySEC
Apr 2021$3 MNo. 2$2 to $10 million

Spine BioPharma, LLC: Raise no. 2, Apr 2021

Investors in this round

1 investor had bought by the notice of Apr 20, 2021: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • John J Viscogliosi · Executive Officer · Manager of the Issuer
  • LLC J Viscogliosi Brothers, · Executive Officer · Member of the Issuer
  • Marc R. Viscogliosi · Executive Officer · Manager and Chief Executive Officer of the Issuer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Marc R. Viscogliosi, Manager and Chief Executive Officer of the Issuer. Source: SEC Form D, newest notice filed Apr 20, 2021. Read the notice at the SEC.

equity, debt, optionsSEC
Mar 2021$5 MNo. 1$2 to $10 million

Spine BioPharma, LLC: Raise no. 1, Mar 2021

Investors in this round

14 investors had bought by the notice of Mar 22, 2021: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Limited Liability Company, incorporated in Delaware

People named in the notice

  • John J Viscogliosi · Executive Officer · Manager of the Issuer
  • LLC J Viscogliosi Brothers, · Executive Officer · Member of the Issuer
  • Marc R. Viscogliosi · Executive Officer · Manager and Chief Executive Officer of the Issuer

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The offering is of Class A Preferred Units”

Signed by Marc R. Viscogliosi, Manager and Chief Executive Officer of the Issuer. Source: SEC Form D, newest notice filed Mar 22, 2021. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Spine BioPharma, LLC chose not to state its revenue in its newest notice of a funding round (Dec 2024).

    SEC Form D · Dec 2024

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Dec 2024

That is all the official record says: Spine BioPharma, LLC has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Spine BioPharma, LLC is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 6 rounds above had up to 14 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Spine BioPharma, LLC
NameRoleNamed in
Fran R. MageeChief Technology OfficerDec 2024
Jason J. GallagherChief Commercial Officer/Chief Operations OfficerDec 2024
Marc R. ViscogliosiDirector and Chief Executive Officer of the IssuerDec 2024
John J ViscogliosiManager of the IssuerApr 2021
LLC J Viscogliosi Brothers,Member of the IssuerApr 2021
Frank R. Cammisa, MDDirectorDec 2024
John J. ViscogliosiDirectorDec 2024
Marc R. ViscogliosiDirector and Chief Executive Officer of the IssuerDec 2024
Thomas R. Bumol, PhDDirectorDec 2024